What is the consensus rating for CHANNEL THERAPEUTICS CORP (CHRO) stock?
The consensus rating for CHANNEL THERAPEUTICS CORP (CHRO) is 82.8571 / 100 . This indicates that analysts generally have a positive outlook on the stock.
CHANNEL THERAPEUTICS CORP (CHRO) Forecast, Price Target & Analyst Ratings
NYSEARCA:CHRO • US1711261057
Current stock price
1.35 USD
+0.09 (+7.14%)
At close:
1.3699 USD
+0.02 (+1.47%)
After Hours:
Analyst forecast overview
View the latest analyst price targets, stock forecast, EPS estimates, revenue projections, revisions, full estimates, rating distribution and upgrades/downgrades for CHANNEL THERAPEUTICS CORP (CHRO).
Forecast Snapshot
Next Earnings Forecast
Earnings Estimate- Release Date
- N/A
- Period
- Q2 / 2025
- EPS Estimate
- -$0.32
- Revenue Estimate
Price Target Details & History
Consensus Price Target and Range
Mean target
N/A
Upside
N/A
From current price of $1.35 to mean target of N/A, Based on 7 analyst forecasts
Low
N/A
Median
N/A
High
N/A
Price Target Revisions
1 Month
0.00%
3 Months
0.00%
Price Target Summary
Analyst Ratings & History
Current Analyst Ratings
Analyst Ratings History
Analyst Ratings Consensus
ChartMill Buy Consensus
82.86%
CHRO was analyzed by 7 analysts. The buy percentage consensus is at 83. So analysts seem to be very confident about CHRO.
In the previous month the buy percentage consensus was at a similar level.
CHRO was analyzed by 7 analysts. More opinions would make the average more meaningful.
Recent Upgrades & Downgrades
| Date | Firm | Action | From → To |
|---|---|---|---|
| 2024-06-18 | Alliance Global Partners | Initiate | Buy |
Next Earnings Forecast Details
Next Earnings Details
- Release Date
- N/A
- Period
- Q2 / 2025
- EPS Estimate
- -$0.32
- Revenue Estimate
- N/A
- Revenue Q2Q
- N/A
- EPS Q2Q
- 0.00%
- Number of Analysts
- 3
Next Earnings Revisions
Revenue (1 Month)
N/A
Revenue (3 Months)
N/A
EPS (1 Month)
0.00%
EPS (3 Months)
0.00%
Next Earnings Summary
Full Analyst Estimates 2024 - 2026
Yearly Earnings Per Share (EPS), Revenue, EBIT, EBITDA and Operating Margin Analyst Estimates
| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | ||
|---|---|---|---|---|---|---|---|---|
| Revenue YoY % growth | 199.9K | N/A -100.00% | N/A | N/A | N/A | N/A | N/A | |
| EBITDA YoY % growth | N/A | N/A | N/A | N/A | N/A | N/A | N/A | |
| EBIT YoY % growth | -1.354M | N/A 38.03% | N/A -176.31% | N/A -196.02% | -7.036M -2.53% | -12.087M -71.79% | -15.606M -29.11% | |
| Operating Margin | -677.29% | N/A | N/A | N/A | N/A | N/A | N/A | |
| EPS YoY % growth | N/A | N/A | N/A | N/A | -1.33 | -1.12 15.38% | -1.07 4.55% |
All data in USD
Quarterly Earnings Per Share (EPS), Revenue, EBIT and EBITDA Analyst Estimates
| Q2 / 25 | Q3 / 25 | Q4 / 25 | |
|---|---|---|---|
| EPS Q2Q % growth | -0.32 | -0.27 8.55% | -0.26 20.31% |
| Revenue Q2Q % growth | N/A | N/A | N/A |
| EBITDA Q2Q % growth | N/A | N/A | N/A |
| EBIT Q2Q % growth | N/A | N/A | N/A |
All data in USD
Yearly Earnings Per Share (EPS) and Revenue Trends vs Historical Data
Long Term Forward Growth Forecast Summary
Long Term EPS Growth (CAGR)
EPS Next 3 Year
5.16%
EPS Next 5 Year
N/A
Long Term Revenue Growth (CAGR)
Revenue Next 3 Year
N/A
Revenue Next 5 Year
N/A
Long Term EBIT Growth (CAGR)
EBIT Next 3 Year
N/A
EBIT Next 5 Year
N/A